Aprea Therapeutics Reports Q2 2026 Financial Results

What Happened

• On August 12, 2026 Aprea Therapeutics, Inc. announced its financial results for the three and six months ended June 30, 2026 via a press release furnished on Form 8-K. The company also provided an update on operations for the same period and updated its corporate presentation slide deck.
• The 8-K was signed by President and CEO Oren Gilad, Ph.D., and includes the press release and the updated slide deck as exhibits.

Key Details

• Filing date: August 12, 2026 (Form 8-K, Items 2.02 and 8.01).
• Reporting periods covered: three and six months ended June 30, 2026.
• Exhibits filed: Exhibit 99.1 — press release (financial results and operational update); Exhibit 99.2 — corporate presentation (August 2026).
• Report signed by Oren Gilad, Ph.D., President and CEO.

Why It Matters

• This filing provides Aprea’s official quarterly results and an updated investor presentation—primary sources investors should review to see revenue, expenses, cash position, pipeline progress, or any guidance disclosed for Q2 2026.
• The updated slide deck may contain refreshed corporate or program information useful for evaluating near-term milestones and the company’s operational status. Investors should read the attached press release and presentation for the specific financial figures and operational details.